Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
21 Novembre 2023 - 2:05PM
Business Wire
Pivotal Phase 3 global study (TransportNPC™)
evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1
(“NPC1”) to be highlighted in a platform presentation
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company focused on
developing transformative therapies for rare and neurological
diseases with limited treatment options, today announced its
abstract has been accepted for platform presentation at the 20th
Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego,
CA.
Details of the platform presentation are as follows:
Title: TransportNPC™: Open Phase 3 global trial of
intravenous hydroxy-propyl-beta-cyclodextrin in patients with
Niemann-Pick disease type C1 (NPC1) Presenter: Dr. Caroline
Hastings, Pediatric hematologist oncologist, Director of
Neuro-oncology, and Professor of Pediatrics at UCSF Benioff
Children’s Hospital Oakland Session: Clinical Applications
Date and Time: Wednesday, February 7, 2024 at 2:00 PM ET
For more information, please visit the conference website
worldsymposia.org.
About WORLDSymposium™
WORLDSymposium™ is an annual research conference dedicated to
lysosomal diseases. WORLD is an acronym that stands for We’re
Organizing Research on Lysosomal Diseases. Since its inception as a
small group of passionate researchers in 2002, WORLDSymposium™ has
grown to an international research conference that attracts over
2000 participants from more than 50 countries around the globe. For
more information, please visit: worldsymposia.org.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical stage biotechnology
company focused on developing transformative therapies for rare and
neurological diseases with limited treatment options. The Company’s
Trappsol® Cyclo™, an orphan drug designated product in the United
States and Europe, is the subject of four formal clinical trials
for Niemann-Pick Disease Type C, a rare and fatal genetic disease,
(www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and
NCT04860960). The Company is conducting a Phase 2b clinical trial
using Trappsol® Cyclo™ intravenously in early Alzheimer’s disease
(NCT05607615) based on encouraging data from an Expanded Access
program for Alzheimer’s disease (NCT03624842). Additional
indications for the active ingredient in Trappsol® Cyclo™ are in
development. For additional information, visit the Company’s
website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about
the company’s current expectations about future results,
performance, prospects and opportunities, including, without
limitation, statements regarding the satisfaction of closing
conditions relating to the offering and the anticipated use of
proceeds from the offering. Statements that are not historical
facts, such as “anticipates,” “believes” and “expects” or similar
expressions, are forward-looking statements. These statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The
factors which may influence the company’s future performance
include the company’s ability to obtain additional capital to
expand operations as planned, success in achieving regulatory
approval for clinical protocols, enrollment of adequate numbers of
patients in clinical trials, unforeseen difficulties in showing
efficacy of the company’s biopharmaceutical products, success in
attracting additional customers and profitable contracts, and
regulatory risks associated with producing pharmaceutical grade and
food products. These and other risk factors are described from time
to time in the company’s filings with the Securities and Exchange
Commission, including, but not limited to, the company’s reports on
Forms 10-K and 10-Q. Unless required by law, the company assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231121966255/en/
Investor Contact:
JTC Team, LLC Jenene Thomas (833) 475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024